Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Figures & data

Table 1 Drugs approved for use in metastatic renal cell carcinoma

Agent	FDA approval	NICE approval	Indication	Comparator	PFS (months)	OS (months)
Interleukin-2^Citation4	1992	Predates NICE	First-line ECOG 0–1	None	19 (median duration response for partial responders)
IFNα^Citation32	2001	Predates NICE	First-line ECOG 0–1	None	5	11.4
Sorafenib^Citation33	2005	Not approved	First-line	Placebo	5.5	19.3
Sunitinib^Citation9	2006	2009	First-line	IFNα	11	26.4
Temsirolimus^Citation10	2007	Available via CDF	First-line Poor risk	IFNα	5.5	10.9
Bevacizumab/IFN^Citation11	2009	Not approved	First-line	IFNα	10.2	23.3
Everolimus^Citation12	2009	Available via CDF	Second-line	Placebo	4.0	14.8
Pazopanib^Citation21	2010	2011	First-line	Placebo	11.1	22.9
Axitinib^Citation14,Citation34	2012	Available via CDF	Second-line	Sorafenib	6.7	20.1

Abbreviations: FDA, Food and Drug Administration; PFS, progression-free survival; OS, overall survival; CDF, Cancer Drugs Fund, UK; NICE, National Institute for Clinical Excellence; ECOG, Eastern Cooperative Oncology Group; IFNα, interferon-alpha.

Figure 1 PISCES study design.

Note: Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved. Escudier BJ, Porta C, Bono P. Patient preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma – PISCES study, NCT 01064310. J Clin Oncol. 2012;30(Suppl 18):Abstr CRA4502.²²
Abbreviations: CT, computed tomography; OD, once daily; SQLQ, Supplementary Quality of Life Questionnaire; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy for fatigue score.

Table 2 Factors to consider in treatment preference between pazopanib and sunitinib

Patient factors (reduced impact on life)		Physician factors
Patient preference for pazopanib	Patient preference for sunitinib
Improved quality of life	Diarrhea	Efficacy
Fatigue	Improved quality of life	Concordance
Changes in food taste	Fatigue	Patient tolerance
Nausea/vomiting	Nausea/vomiting	Patient preference
Soreness in mouth/throat	Appetite	Mode of administration
Soreness in hands/feet	Stomach pain	Ability to adjust dose/regimen
Stomach pain	Soreness in mouth/throat	Comorbidities
Diarrhea	Soreness in hands/feet	Experience with the drug
Hair color change	Changes in food taste	Support structure
Time on treatment	Hair color change

Note: Data from Escudier BJ et al.²²

FyfeGFisherRIRosenbergSASznolMParkinsonDRLouieACResults of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyJ Clin Oncol19951336886967884429

 PubMed Web of Science ®Google Scholar

MinasianLMMotzerRJGluckLMazumdarMVlamisVKrownSEInterferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-upJ Clin Oncol1993117136813758315435

 PubMed Web of Science ®Google Scholar

EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530

 PubMed Web of Science ®Google Scholar

MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529

 PubMed Web of Science ®Google Scholar

HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086

 PubMed Web of Science ®Google Scholar

EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031

 PubMed Web of Science ®Google Scholar

MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228

 PubMed Web of Science ®Google Scholar

SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962

 PubMed Web of Science ®Google Scholar

RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247

 PubMed Web of Science ®Google Scholar

MotzerRJEscudierBTomczakPAxitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trialLancet Oncol201314655256223598172

 PubMed Web of Science ®Google Scholar

EscudierBJPortaCBonoPPatient preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, crossover study in patients with metastatic renal cell carcinoma – PISCES study, NCT 01064310J Clin Oncol201230Suppl 18 Abstr CRA4502

 Google Scholar